Endocrinology

Empagliflozin sees topline success in CKD trial

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD

Yesterday

In patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD), treatment with canagliflozin safely decreases the risk of developing end-stage renal disease, reports a new Japan study.

Curcumin a promising adjuvant lipid-lowering agent

Yesterday

A recent study has revealed that curcumin exerts favourable effects on the lipid profile, with its intake helping lower levels of total cholesterol, triglycerides, low-density lipoprotein and high-density lipoprotein cholesterol.

Add-on DPP4i, GLP1Ra as good as insulin for in-hospital diabetes management

3 days ago

The use of dipeptidyl peptidase 4 inhibitors (DPP4i) and sodium glucose co-transporter 2 inhibitors (SGLT2i) for diabetic patients admitted to hospitals yields the same efficacy and safety outcomes as insulin, according to the results of a systematic review and meta-analysis.

What do young T1DM patients look for in ketone breath sensors?

Tristan Manalac, 4 days ago

Young patients with type 1 diabetes mellitus (T1DM) find the noninvasive nature of ketone breath sensor devices attractive, especially as compared with blood testing, according to a recent study. Still, concerns about such devices remain, including their ease of use, accuracy, and affordability.

$Vitamin D supplementation flops for fracture prevention$

Vitamin D supplementation flops for fracture prevention

4 days ago

Intake of supplemental vitamin D3 falls short of reducing the incidence of fractures among generally healthy midlife and older adults as compared with placebo, according to data from the Vitamin D and Omega-3 Trial (VITAL).

$Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum$

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

14 Jan 2022

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

18 Nov 2021

Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.

Clinical benefits of flash glucose monitoring with FreeStyle Libre™

15 Sep 2021

Various studies have shown the beneficial effects of the FreeStyle Libre™ flash glucose monitoring system for the continuous monitoring of glucose levels in type 1 and type 2 diabetes (T1D and T2D) patients. While clinical trials have demonstrated a reduced time in hypoglycaemia, fewer hypoglycaemic events per day, and significant reduction in glycated haemoglobin (HbA1c), real-world data have shown improved glycaemic control in these patients.

Optimising glycaemic control with FreeStyle Libre™ for better patient management

15 Sep 2021

The FreeStyle Libre™ flash glucose monitoring system includes a sensor which automatically measures and continuously stores up to 8 hours of glucose readings, allowing patients to monitor their glucose levels without the need for painful finger pricks. Physicians play an important role in reviewing and analysing glucose data that is available through LibreView to support patient management.

Fezolinetant reduces hot flashes during menopause

Roshini Claire Anthony, 01 Aug 2022

The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.

Timing of liquid LT4 intake doesn’t impact bioavailability

Elvira Manzano, 01 Aug 2022

Bioavailability studies presented at ENDO 2022 showed that patients with hypothyroidism can safely take the liquid formulations of levothyroxine (LT4) 15 or 30 minutes before meals, without having to worry about food effect on bioavailability.

Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD

Audrey Abella, 27 Jul 2022

In adults with overweight/obesity and nonalcoholic fatty liver disease (NAFLD), daily administration of growth hormone (GH) reduced hepatic steatosis and improved markers of hepatic inflammation and fibrosis, a study has shown.

Empagliflozin shows promise for chronic SIAD-induced hyponatremia

Audrey Abella, 26 Jul 2022

The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.

10 percent long-term weight loss with lifestyle management, medication in overweight/obese patients

Obese/overweight patients incur 10 percent long-term weight loss with lifestyle management, medication

Roshini Claire Anthony, 25 Jul 2022

Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.

Prediabetes may up MI, PCI, CABG risk

Roshini Claire Anthony, 21 Jul 2022

Individuals with prediabetes appear to be at an elevated risk of developing myocardial infarction (MI) as well as requiring coronary interventions, according to a study presented at ENDO 2022.

Testosterone therapy safe for the heart, but some experts disagree

Elvira Manzano, 08 Jul 2022

Testosterone therapy appeared safe for the heart in men with hypogonadism, according to a meta-analysis of 35 placebo-controlled trials presented at ENDO 2022. However, experts have differing opinions on the findings.